IBI112
Sponsors
Innovent Biologics (Suzhou) Co. Ltd., Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Conditions
Psoriasis
Phase 3
A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis
CompletedNCT05645627
Start: 2023-02-10End: 2024-08-01Updated: 2024-10-29
IBI112 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment
CompletedNCT06049810
Start: 2023-10-10End: 2025-07-28Updated: 2025-08-17
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RecruitingNCT07265284
Start: 2025-12-03End: 2029-01-31Target: 104Updated: 2025-12-22